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TLR2 recognises bacterial lipopeptides and lipoteichoic acid, and forms heterodimers with TLR1 or TLR6. TLR2 is
relatively well characterised in mice and humans, with published crystal structures of human TLR2/1/Pam3CSK4 and
murine TLR2/6/Pam2CSK4. Equine TLR4 is activated by a different panel of ligands to human and murine TLR4, but
less is known about species differences at TLR2. We therefore cloned equine TLR2, TLR1 and TLR6, which showed
over 80% sequence identity with these receptors from other mammals, and performed a structure-function analysis.
TLR2/1 and TLR2/6 from both horses and humans dose-dependently responded to lipoteichoic acid from
Staphylococcus aureus, with no significant species difference in EC50 at either receptor pair. The EC50 of Pam2CSK4
was the same for equine and human TLR2/6, indicating amino acid differences between the two species’ TLRs do
not significantly affect ligand recognition. Species differences were seen between the responses to Pam2CSK4 and
Pam3CSK4 at TLR2/1. Human TLR2/1, as expected, responded to Pam3CSK4 with greater potency and efficacy than
Pam2CSK4. At equine TLR2/1, however, Pam3CSK4 was less potent than Pam2CSK4, with both ligands having
similar efficacies. Molecular modelling indicates that the majority of non-conserved ligand-interacting residues are
at the periphery of the TLR2 binding pocket and in the ligand peptide-interacting regions, which may cause subtle
effects on ligand positioning. These results suggest that there are potentially important species differences in
recognition of lipopeptides by TLR2/1, which may affect how the horse deals with bacterial infections.Introduction
Pathogen-associated molecular pattern recognition re-
ceptors (PRRs) on host cells detect pathogens and their
associated ligands to initiate innate immune responses
and drive inflammation. Toll-like receptors (TLRs) are the
best characterised of the PRRs, and recognise predomin-
antly bacterial and/or viral ligands. Bacterial lipoproteins,
lipoteichoic acid (LTA) and peptidoglycan (PepG), are
recognised by TLR2, which forms heterodimers with
either TLR1 or TLR6 [1-3]. In mice and humans, the
TLR2/1 heterodimer recognises triacylated lipopeptides,
such as N-palmitoyl-S-[2,3-bis(palmitoyloxy)-propyl]-
(R)-cysteinyl-(lysyl)3-lysine (Pam3CSK4), whereas the
TLR2/6 complex recognises diacylated lipopeptides, for
example S-[2,3-bis(palmitoyloxy)-propyl]-(R)-cysteinyl-
(lysyl)3-lysine (Pam2CSK4) [1,2,4]. The TLR2/1 hete-
rodimer also recognises diacylated ligands such as* Correspondence: ceb27@cam.ac.uk
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reproduction in any medium, provided the ormacrophage-activating lipopeptide 2 (MALP-2) and
Pam2CSK4 [4]. Crystal structures for human TLR2/1
bound to Pam3CSK4 and murine TLR2/6 bound to
Pam2CSK4 have been solved, and demonstrate the same
heterodimeric structure with 1:1:1 TLR2:TLR1/6:ligand
stoichiometry [1,2].
TLR2 knockout mice are hyper-susceptible to Gram
positive bacterial infections, but resistant to Gram posi-
tive bacterial ligands, and humans with mutations in the
TLR2 gene have altered Gram positive infection suscep-
tibility [5-7]. TLR2 recognition of Gram positive bacteria
is, therefore, fundamental to successfully controlling in-
fections with these organisms. Gram positive bacterial
infections in young horses are common, and involved in
a range of syndromes from reduced performance in young
racing thoroughbreds to life-threatening sepsis in neo-
nates [8,9]. Equine peripheral blood mononuclear cells
(PBMC) stimulated with the TLR2/1 ligand Pam3CSK4
produce tumour necrosis factor-α (TNF-α), and LTA and
PepG also stimulate release of TNF-α in equine whole
blood assays [10,11]. These findings suggest TLR2 recog-
nition of bacterial ligands is important in the horse, buttd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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the binding pockets of equine TLR2/1 and TLR2/6
heterodimers, which is important for targeting future ther-
apeutics. TLR2 antagonists could be useful for the treat-
ment of Gram positive bacterial disease, and agonists
useful as potential vaccine adjuvants.
Species differences in ligand recognition at TLRs are
common, and, at TLR4/MD-2 for example, the underlying
molecular mechanisms are becoming clearer [12]. Equine,
human and murine TLR4/MD-2 show distinct profiles of
ligand recognition, for example signalling to lipid IVa, and
comparative molecular studies have been important in un-
derstanding how different ligands generate active signal-
ling complexes [13,14]. Much less is known about ligand
specificity at TLR2 in complex with co-receptors TLR1 or
TLR6 in species other than humans and mice, however.
In this study, we cloned equine TLR2, TLR1 and TLR6.
We performed a structure-function analysis to determine
whether the equine receptors respond to classical human/
murine TLR2 ligands, and with the same pharmacological
phenotype as the human receptors. Our results demon-
strate that subtle structural and functional species differ-
ences exist in recognition of lipopeptides by the TLR2/1
heterodimer. Pam3CSK4 responses were diminished at
equine TLR2/1, which suggests the horse could have a
dampened response to triacylated lipopeptides in general.
This may have implications for therapeutic manipulation
of equine TLR2, and could potentially indicate altered sus-
ceptibility to specific bacterial infections.
Materials and methods
Cells
Total RNA was isolated from either an equine macro-
phage line (EML) [15] or primary equine vascular smooth
muscle (VSM). VSM cells were cultured from aorta re-
moved post mortem from a horse euthanased at the
Queen’s Veterinary School Hospital, University of Cam-
bridge on welfare grounds, and for reasons unrelated to
this study. SW620 cells were a gift from Richard Tapping
and maintained in RPMI (Sigma-Aldrich, Poole, UK)
supplemented with 10% foetal calf serum (FCS; Hyclone,
Thermo Scientific, Cramlington, UK), 2 mM glutamine,
100 IU/mL penicillin and 100 μg/mL streptomycin (re-
ferred to as “complete SW620 medium”) [4]. HEK293 cells
were purchased from ATCC and maintained in Dulbecco’s
Modified Eagle medium (DMEM; Sigma-Aldrich) sup-
plemented with 10% FCS, 2 mM l-glutamine, 100 IU/mL
penicillin and 100 μg/mL streptomycin (referred to as
“complete HEK medium”). Cells were grown at 37°C/5%
CO2 and subcultured every 2-3 days.
RNA isolation
Total RNA was isolated from cells using the RNeasy plus
mini-kit (Qiagen, Manchester, UK). RNA yield and integritywere assessed by spectrophotometry and agarose gel elec-
trophoresis (AGE) respectively.
RT-PCR and cloning of full length equine TLR1, -2 and -6
Primers for amplification of equine TLR2, -1 and -6 by
reverse transcriptase PCR (RT-PCR) were based on the
published full-length cloned or predicted equine se-
quences. Primer sequences included restriction sites at the
5′ and 3′ termini to facilitate ligation into pcDNA3. First-
strand cDNA was synthesised using the High Fidelity
Transcriptor cDNA Synthesis Kit (Roche, Welwyn Garden
City, UK) as follows: 1 μg of total RNA was incubated with
10 μM gene-specific reverse primer at 65°C for 5 min; re-
verse transcription master-mix comprising 5× Reaction
Buffer, 10 mM dNTP, RNase inhibitor and High Fidelity
Reverse Transcriptase (RT) was added to the denatured
RNA, and mixtures incubated at 42°C for 1 h; RT enzyme
was then inactivated by heating at 70°C for 10 min.
First-strand cDNA was stored at -80°C or amplified by
PCR using Phusion High-Fidelity (HF) DNA Polymerase
(Thermo Scientific), according to the following recipe:
18.25 μL nuclease-free water, 2.5 μL 5× Phusion HF buf-
fer, 0.5 μL 10 mM dNTP, 1.25 μL 10 μM forward primer,
1.25 μL 10 μM reverse primer, 2 μL first-strand cDNA
template and 0.25 μL Phusion HF DNA Polymerase.
The PCR protocol involved an initial denaturation step
at 98°C for 3 min, followed by 34 cycles of denaturation
at 98°C for 30 s, annealing at 55°C for 30 s, extension at
72°C for 1 min 30 s, and a final elongation step at 72°C
for 10 min. PCR products of 2.5 kb, 2.6 kb and 2.4 kb,
corresponding to full length equine TLR2, TLR1 and TLR6
respectively, were obtained by AGE and purified by gel ex-
traction using the GeneJET gel extraction kit (Fermentas,
Thermo Scientific). A-tailed PCR products were ligated
into pGEM-T Easy Vector (Promega, Southampton, UK)
and sequenced by conventional Sanger sequencing. Cloned
sequences were compared with published sequences for
equine TLR2 [GenBank:AY429602], TLR1 [GenBank:NM_
001256899] and TLR6 [Genbank:NM_001257142], as ap-
propriate, to verify the correct product was obtained.
Sequenced products were then subcloned into pcDNA3
expression vector for functional studies.
RT-PCR for detection of human TLRs
Internal primers for detection of human TLRs were
designed using PrimerBLAST. Total RNA isolated from
SW620 and HEK293 cells was subjected to DNase
(Fermentas, Thermo Scientific) treatment to remove
contaminating genomic DNA (gDNA) as follows: 8 μL
(800 ng) total RNA was incubated with 1 μL DNaseI
buffer and 1 μL DNaseI for 30 min at 37°C; 1 μL RNase-
free EDTA was added and mixtures heated for 10 min at
65°C to inactivate the DNase. First-strand cDNA was then
synthesised in a two-step process, using the SuperScript
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Life Technologies, Paisley, UK): 6 μL DNase-treated total
RNA was incubated with 1 μL 50 mM oligo dT and 1 μL
8× Annealing Buffer for 5 min at 65°C, then placed on ice;
10 μL 2× First-Strand Reaction Mix and 2 μL Superscript
III/RNaseOUT Enzyme Mix were added and mixtures in-
cubated at 50°C for 50 min. RNase was then inactivated
by heating to 85°C for 5 min. cDNA was amplified by
PCR using DreamTaq polymerase (Fermentas, Thermo
Scientific) and gene-specific primers according to the fol-
lowing recipe: 12.88 μL nuclease-free water, 2.5 μL 10×
DreamTaq buffer, 0.5 μL 10 mM dNTP, 0.5 μL 10 μM
forward primer, 0.5 μL 10 μM reverse primer, 8 μL
DNase-treated first-strand cDNA template and 0.125 μL
DreamTaq DNA Polymerase. The PCR protocol involved
an initial denaturation step at 95°C for 2 min, followed by
25-35 cycles of denaturation at 95°C for 30 s, annealing
for 30 s, extension at 72°C for 50 s, and a final elongation
step at 72°C for 15 min. Primer annealing temperatures
were defined in preliminary optimisation experiments
as follows: TLR4: 62.1°C; TLR2 and TLR1: 63.9°C;
TLR6: 58.5°C; glyceraldehyde 3-phosphate dehydrogen-
ase (GAPDH): 70.1°C. Negative control PCR reactions
used DNase-treated total RNA instead of DNase-treated
first-strand cDNA template, using an equal quantity of
total RNA for fair comparison. Expression of TLRs was
determined by AGE.Structural modelling
Three-dimensional structure images were generated using
PyMol. The human TLR2/1 heterodimer crystal structure
was downloaded from the Protein Data Bank [PDB:2Z7X].
A structural model of human TLR6 was generated using
SWISS-MODEL, with the murine TLR6 crystal structure
as a template [PDB:3A79] [16-19]. Structural models of the
equine receptors were generated in the same way, using
crystal structures of human TLR2, human TLR1 and mur-
ine TLR6. The human TLR1 TIR image was generated
from the crystal structure [PDB:1FYV]. Pairwise protein se-
quence alignments of human and equine TLR1, -2 and -6
were generated with ClustalW Local Alignment tool.
Variant residues within our cloned equine receptors
were identified following alignment with published
predicted and cloned equine sequences in ClustalW
Pairwise Nucleotide alignment. Sequence alignments
between human, equine and murine receptors were gen-
erated using ClustalW Multiple Sequence Alignment
tool, and using standard settings.Bacterial ligands
Racemic mixtures of Pam2CSK4 and Pam3CSK4, and
purified LTA from Staphylococcus aureus, were purchased
from Invivogen, Source BioScience, Cambridge, UK.Transient transfection and stimulation of SW620 cells
SW620 cells (a gift from Richard Tapping, USA) were
utilised for TLR2/1 and TLR2/6 transient transfection
experiments, as, unlike HEK293 cells, they are 1) deficient
in significant expression of all three receptors, and 2)
poorly responsive to Pam2CSK4 and Pam3CSK4 without
exogenously added TLRs (Additional file 1) [4]. This cell
line also does not express CD14, which is required for effi-
cient recognition of lipopeptides and LTA by TLR2 but
does not alter the pattern of agonism displayed by syn-
thetic ligands [4,20,21]. SW620 cells were seeded at 3.75 ×
104 cells per well of a 48 well plate and transiently
transfected 24 hours later using Fugene 6 (Promega) at a
ratio of 1 μg DNA: 4 μL Fugene 6. For transfection, ex-
pression vectors containing cDNA encoding human (in
pFLAG-CMV) or equine (in pcDNA3) TLR2, -1 and -6,
and CD14 (in pcDNA3), were mixed as appropriate. TLR
cDNA-containing vectors were used at 2.5 ng/well; CD14
cDNA-containing vectors were used at 1.25 ng/well. TLR
constructs were replaced with empty vector (pcDNA3), as
appropriate, to balance total added DNA amounts. Re-
porter constructs pNF-κB-luc (Clontech; 25 ng/well) and
ph-RG-TK (Promega; 12.5 ng/well), encoding firefly lucif-
erase under an NF-κB promoter and constitutively ex-
pressed Renilla luciferase respectively, were then added to
all receptor mixtures, together with 10× Tris-EDTA (TE).
Following mixing of DNA, and per 4 wells, 0.7 μL Fugene
6 was diluted to 10 μL in serum- and antibiotic-free RPMI
and incubated for 5 min. DNA mixtures were then added
to the Fugene 6/RPMI mixtures and incubated for 30 min
at room temperature. Following incubation, transfection
mixtures were diluted to 1 mL per 4 wells in complete
SW620 medium. Old medium was removed from plated
cells and replaced with the transfection/complete medium
mixtures. Twenty four hours post-transfection, cells were
stimulated with either bacterial ligands diluted in RPMI
containing 0.1% FCS (to provide a source of lipopolysac-
charide binding protein (LBP)), or this medium alone as a
control. Old media were removed before the addition of
stimulation media. Cells were stimulated for six hours,
lysed using diluted passive lysis buffer (PLB; Promega),
and NF-κB activation measured by the dual luciferase re-
porter assay (Promega).
Transient transfection and stimulation of HEK293 cells
HEK293 cells were seeded at a density of 3 × 104 cells per
well of a 96 well plate and transiently transfected 48 h
later using JetPEI (Polyplus). For transfection, expression
vectors containing cDNA encoding human TLR2, -1 and
-6, and CD14, were mixed as appropriate. TLR cDNA-
containing and CD14 cDNA-containing vectors were used
at 1 ng/well. TLR constructs were replaced as appropriate
with empty vector (pcDNA3) to balance the total added
DNA amounts. pNF-κB-luc (10 ng/well) and ph-RG-TK
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10× TE and 150 mM NaCl to give a total volume of 50 μL
per 10 wells. Following mixing of DNA, and per 10 wells,
2 μL JetPEI was added to 48 μL 150 mM NaCl. JetPEI/
NaCl was added to the DNA mixtures at a 1:1 ratio and
incubated for 30 min at room temperature. Following in-
cubation, transfection mixtures were diluted to 1 mL per
10 wells in complete HEK medium. Old medium was
removed from plated cells and replaced with the transfec-
tion/complete medium mixtures. Forty eight hours post-
transfection, cells were stimulated with either bacterial
ligands diluted in DMEM containing 0.1% FCS (to provide
LBP), or this medium alone as a control. Old media were
removed before the addition of stimulation media. Cells
were stimulated for six hours, lysed using diluted PLB,
and NF-κB activation measured by the dual luciferase re-
porter assay (Promega).
Statistical analysis
Experiments were undertaken three times (n = 3) to en-
sure qualitative repeatability, and results shown from a
representative experiment [4,13,22]. Multiple comparisons
were performed using unpaired two-tailed t-tests with
Bonferroni correction, and with Welch’s correction for
unequal variances as appropriate. Dose response curves
were fitted by non-linear regression to a sigmoidal dose-
response (variable slope) model, using GraphPad Prism
software, to allow determination of EC50 and the associ-
ated 95% confidence intervals (CI). For comparison of
curves, best fit values for maximum stimulation and
logEC50 were compared using F tests.
Results
Equine TLR2, -1 and -6 share high sequence identities
with the human and murine receptors
Total RNA was harvested from equine cells and used to
generate cDNA encoding equine TLR2, -1 and -6 by RT-
PCR. Comparison of our constructs with the human
receptor sequences revealed 81%, 81% and 80% whole re-
ceptor sequence identities respectively (Additional file 2).
The ectodomains of TLR2, -1 and -6 were the least con-
served regions (78%, 79% and 77% respectively), whereas
the TIR domains were the most conserved (93%, 89% and
91% respectively). Full-length sequence alignments are
shown in Additional file 3.
Within the GenBank database, equine TLR2 and TLR1
sequences are available from cloned receptors, whereas
the sequence for equine TLR6 is predicted. On compari-
son of our cloned receptors with the published sequences,
several variations were present. All changes were found to
be non-synonymous. The ultra-high fidelity enzyme
Phusion HF was used for amplification of single-strand
cDNA sequences, and so cloning errors due to low en-
zyme specificity are unlikely. The sequence differencestherefore probably reflect true population variability. To
determine the potential functional significance of the
variant residues, models of the equine receptors were gen-
erated based on crystal structures for the human and mur-
ine receptors, and variant residues mapped to show their
location relative to ligand-binding and dimerisation sites
[1,2,16-19].
One variant residue, L773W, was found in equine
TLR1 (residues are labelled as changes from published
equine→ our cloned equine receptors). This residue is
located in the TIR domain, well away from the BB loop,
and represents a change from a small to bulkier non-
polar residue (Additional file 4A). The equivalent W769
is present within human TLR1. A variant (V118L) that is
present in a published partial equine TLR1 cDNA was
not found in our construct [GenBank: EF581164.1]. The
variations within equine TLR2 (R357Q, K509P and
H579R) are all equivalent to the human or murine resi-
dues. None of these residues are located immediately ad-
jacent to the binding pocket or the main dimerisation
interface, and are therefore unlikely to interact with the
ligand or interfere with dimerisation (Additional file 4B).
Three variations are present within equine TLR6 (V452I,
V486A and L580S), and located well away from the bind-
ing pockets (Additional file 4C). Only variant residues
close to the dimerisation interfaces are shown for TLR2
and TLR6.
Staphylococcus aureus LTA activates equine and human
TLR2 heterodimers with similar potency
LTA is a major component of the Gram positive cell
wall, and its recognition by TLR2 is probably a key initi-
ator of Gram positive sepsis in humans [23,24]. Crystal-
lography so far has shown binding of an inactive form of
LTA from Streptococcus pneumoniae (pnLTA) to murine
TLR2, but the dimeric structure of TLR2 bound to bio-
logically active LTA has not been solved [1]. It is also
unclear whether LTA signals through TLR2/1, TLR2/6
or both. We therefore constructed dose response curves
for equine and human TLR2/1 and TLR2/6 to purified
LTA from Staphylococcus aureus, using the human
SW620 cell line. SW620 cells do not signal to TLR2 li-
gands, and respond very poorly when transfected with
human TLR2 alone (Additional file 1C). Reconstitution
of the TLR2/1 and TLR2/6 dimers is therefore required
for robust signalling by this cell line to TLR2 ligands,
which allows species-specific TLR2 dimer responses to
be studied more reliably than in HEK293 cells.
SW620 cells were transiently transfected with reporter
constructs and one of four receptor combinations: human
TLR2+TLR1+CD14, human TLR2+TLR6+CD14, equine
TLR2+TLR1+CD14 or equine TLR2+TLR6+CD14, and
stimulated with increasing doses of ligand. EC50 and
maximum stimulation values were determined at each
Figure 1 Responses of human and equine TLR2/1 and TLR2/6
to LTA. SW620 cells were transiently transfected with human TLR2
(hTLR2) and human TLR1 (hTLR1), hTLR2 and human TLR6 (hTLR6),
equine TLR2 (eqTLR2) and equine TLR1 (eqTLR1), or eqTLR2 and
equine TLR6 (eqTLR6), together with the cognate species’ CD14 and
reporter constructs NF-κB-luc and Renilla luciferase. Cells were
stimulated 24 hours later with increasing doses of LTA from
Staphylococcus aureus. Cells were stimulated for six hours, lysed, and
analysed for luciferase activity. Data are from a representative
experiment and expressed as triplicate mean ± standard error of the
mean (SEM) for that experiment. (A) LTA dose-dependently
stimulated human TLR2/1 and TLR2/6. Maximum stimulation of
human TLR2/6 was higher than human TLR2/1. (B) LTA dose-
dependently stimulated equine TLR2/1 and equine TLR2/6.
Maximum stimulation of equine TLR2/6 was higher than TLR2/1. (C)
Data for each curve were normalised for calculation of EC50, using
medium alone as 0% and maxima for each curve (raw data) from
(A) and (B) as 100%. EC50 values were not significantly different for
human and equine receptor pairs, nor between equine receptor
pairs. Human TLR2/1 and TLR2/6 had significantly different
EC50 values.
Irvine et al. Veterinary Research 2013, 44:50 Page 5 of 11
http://www.veterinaryresearch.org/content/44/1/50heterodimer as measures of ligand potency and efficacy re-
spectively. LTA efficacy was significantly higher at TLR2/6
than TLR2/1 for both species’ heterodimers (Figure 1A
and 1B). The EC50 for LTA at human TLR2/1 (16.82 ng/
mL (95% C.I. 9.82-26.49)) was significantly lower than that
at human TLR2/6 (63.59 ng/mL (95% C.I. 51.47-78.56)),
whereas potency at the equine TLR2 heterodimers was not
significantly different (equine TLR2/1 EC50 = 27.11 ng/mL
(95% C.I. 16.22-48.29); equine TLR2/6 EC50 = 39.32 ng/
mL (95% C.I. 22.31-69.29); Figure 1C). The calculated
EC50 values were also not significantly different be-
tween species for LTA at TLR2/1 or at TLR2/6. These
findings show that S. aureus LTA activates both TLR2/1
and TLR2/6 analogously in the two species, with no
clear species-specific behaviour.
Species differences are present between equine and
human TLR2/1 responses to Pam2CSK4 and Pam3CSK4
Pam2CSK4 and Pam3CSK4 are synthetic lipopeptides
that are diacylated and triacylated respectively [3]. The
availability of crystal structures for murine TLR2/6/Pam
2CSK4 and human TLR2/1/Pam3CSK4 makes these li-
gands excellent candidates for structure-function analysis.
We constructed dose responses curves to Pam2CSK4 or
Pam3CSK4 in transfected SW620 cells. Pam2CSK4 and
Pam3CSK4, as expected, stimulated human TLR2/1 dose-
dependently, with higher efficacy observed for Pam3CSK4
at this receptor heterodimer (Figure 2A). The EC50 values
for Pam2CSK4 and Pam3CSK4 at human TLR2/1 were
significantly different, with Pam2CSK4 having an EC50 of
4.21 ng/mL (95% confidence interval (C.I.) 2.34-7.50) and
Pam3CSK4 an EC50 of 0.47 ng/mL (95% C.I. 0.28-0.79)
(Figure 2B). Pam3CSK4 is therefore stronger than
Pam2CSK4 at human TLR2/1. Dose response curves for
Pam2CSK4 and Pam3CSK4 at equine TLR2/1 demon-
strated two key differences to the curves obtained for
human TLR2/1. Firstly, Pam2CSK4 and Pam3CSK4 effica-
cies at equine TLR2/1 were the same (Figure 2C). Sec-
ondly, the EC50 for Pam3CSK4 (18.73 ng/mL (95% C.I.
12.95-27.08)) was higher than for Pam2CSK4 (0.43 ng/mL
(95% C.I. 0.13-1.48)) (Figure 2D) which is in contrast to
the results for human TLR2/1. Pam3CSK4 is therefore less
potent than Pam2CSK4 at equine TLR2/1. Pam2CSK4
was also 10-fold more potent at equine TLR2/1 than at
human TLR2/1. These findings demonstrate TLR2/1 rec-
ognition of these synthetic lipopeptides is somewhat dif-
ferent between the horse and human.
The EC50 values for Pam2CSK4 at human TLR2/6
(0.015 ng/mL (95% C.I. 0.009-0.027)) and equine TLR2/6
(0.010 ng/mL (95% C.I. 0.004-0.024)) were not signifi-
cantly different (Figure 3). Pam3CSK4 failed to stimulate
TLR2/6 from either species (data not shown). These
findings show Pam2CSK4 recognition by equine TLR2/6
is analogous to human TLR2/6 recognition.
Figure 2 Responses of human and equine TLR2/1 to synthetic
ligands. SW620 cells were transiently transfected with hTLR2 and
hTLR1 or eqTLR2 and eqTLR1, together with the cognate species’
CD14 and reporter constructs NF-κB-luc and Renilla luciferase. Cells
were stimulated 24 hours later with increasing doses of synthetic
ligands Pam2CSK4 and Pam3CSK4. Cells were stimulated for six hours,
lysed, and analysed for luciferase activity. Data are from a
representative experiment and expressed as triplicate mean ± SEM for
that experiment. (A) Pam3CSK4 and Pam2CSK4 stimulated human
TLR2/1 dose-dependently, and maximum stimulation by Pam3CSK4
was higher than for Pam2CSK4. (B) Data from (A) were normalised for
calculation of EC50, using medium alone as 0% and maxima for each
curve (raw data) from (A) as 100%. EC50 values were significantly
different for the two ligands, with the Pam2CSK4 curve shifted to the
right relative to Pam3CSK4. (C) Pam2CSK4 and Pam3CSK4 stimulated
equine TLR2/1 dose-dependently, and maximum stimulation by both
ligands was the same. (D) Data from (C) were normalised for
calculation of EC50, using medium alone as 0% and maxima for each
curve (raw data) from (C) as 100%. The curve for Pam3CSK4 was
shifted to the right, and EC50 values were significantly different.
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structures reveals potential differences at the ligand
interaction interfaces
Residues within human TLR2/1 responsible for ligand
binding and dimerisation have been identified [2]. We
compared the equine and human receptors to determine
whether non-conservative changes between the two spe-
cies’ sequences are located in areas of the proteins that
could affect ligand association, and explain species speci-
ficity at TLR2/1. Human-equine non-conserved residues
are spread diffusely across both receptor ectodomains
(data not shown). The binding pockets of TLR2 and TLR1
are lined predominantly with human-equine conserved
residues, whereas the regions of the two receptors flanking
the ligand peptide group are virtually all non-conserved
(Additional file 5). Seven of the twenty four residues of
human TLR2 that interact with Pam3CSK4 in the crystal
structure are non-conserved between human and equine,
but these lie mainly on the periphery of the ligand binding
pocket (Figure 4A). All but three of the TLR dimerisation
residues of TLR2 are conserved between the two species,
and all of the residues that interact with both the ligand
and form the dimerisation interface are also conserved
(not shown). Two of the eighteen residues in human
TLR1 that interact with Pam3CSK4 are non-conserved be-
tween the two species (Figure 4A), and all but four of the
main dimerisation interface residues are conserved (not
shown). Of the two non-conserved residues, only V339
(I343 in the equine) contacts the amide acyl chain of
Pam3CSK4. In summary, nine ligand-binding and seven
dimerisation residues differ between the equine and hu-
man TLR2/1 dimers, which could potentially explain theFigure 3 Responses of human and equine TLR2/6 to
Pam2CSK4. SW620 cells were transiently transfected with hTLR2
and hTLR6 or eqTLR2 and eqTLR6, together with the cognate
species’ CD14 and reporter constructs NF-κB-luc and Renilla
luciferase. Cells were stimulated 24 hours later with increasing doses of
Pam2CSK4. Cells were stimulated for six hours, lysed, and analysed for
luciferase activity. Data are from a representative experiment and
expressed as triplicate mean ± SEM for that experiment. Pam2CSK4
stimulated human and equine TLR2/6 dose-dependently. Data were
normalised for calculation of EC50, using medium alone as 0% and
maxima for each curve (raw data) as 100%. EC50 values were not
significantly different for human and equine receptors.
Figure 4 Species-differences of the ligand binding pockets of TLR2/1. Crystal structures of human TLR2 and TLR1 [PDB code 2Z7X], and a
model of human TLR6, were viewed in PyMol and non-conserved residues between the human and horse highlighted. (A) Conserved TLR2
ligand-binding residues (cyan) form the majority of contacts, whereas non-conserved (magenta) are at the periphery of the pocket. The TLR1
pocket is lined with conserved residues (yellow); only G313 and V339 (lilac; S317 and I343 in the horse) are non-conserved. (B) L318 (green) and
F319 (blue), which interact with Pam2CSK4 (red), are conserved in the horse (I318 and F319). The region surrounding L318 and F319 is conserved
apart from F317 (Y317 in the horse; cyan), which lies immediately lateral to L318. F343 and F365 (magenta), which block the TLR6 pocket, are
also shown.
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receptor pair.
In the mouse TLR2/6/Pam2CSK4 crystal structure, two
residues only (L318 and F319) within TLR6 are shown to
interact directly with Pam2CSK4 [1]. The shallow binding
pocket of human TLR6 is flanked and lined by human-
equine conserved residues, except for F317 (Y317 in the
horse), which lies immediately lateral to L318 (I318 in the
horse) and forms part of the main dimerisation interface
(Figure 4B). Given the equipotency of Pam2CSK4 and
LTA at horse and human TLR2/6, the effect of this residue
change appears negligible. The two phenylalanines, F343
and F365, that block the entrance to the TLR6 pocket and
prevent entry of an acyl chain are conserved between
human, horse and mouse (Additional file 6).
Species differences in TLR2/1 signalling are dependent on
both TLR2 and TLR1
The amino acid residues identified by structural modelling
suggested both TLR2 and TLR1 could be required for the
species differences seen in the lipopeptide responses. To
test this hypothesis, we transfected SW620 cells with
human TLR2+TLR1+CD14, equine TLR2+TLR1+CD14,
human TLR2+CD14+equine TLR1, or equine TLR2+CD
14+human TLR1. Cells were stimulated with Pam2CSK4 at
20 ng/mL, Pam3CSK4 at 20 ng/mL, or medium alone. A
ligand concentration of 20 ng/mL was selected from our
preliminary dose response curve analyses and comparison
with published data, as this dose induces submaximal re-
sponses for both ligands [4,25]. The Pam3CSK4 response
was higher than Pam2CSK4 at human TLR2/1, yet lower
than Pam2CSK4 at equine TLR2/1, consistent with the
dose response curves (Figure 5A). Human TLR2/equine
TLR1 and equine TLR2/human TLR1 each signalled
similarly to both ligands, however, with no statisticallysignificant difference in signal between ligands detected at
either receptor combination. Replacing equine TLR2 or
TLR1 with the equivalent human receptor therefore did
not replicate the human TLR2/1 response pattern to these
ligands, which indicates residues in both equine TLR2 and
equine TLR1 contribute to the observed equine TLR2/1
responses to Pam2CSK4 and Pam3CSK4.
To ensure that the observed species differences to
Pam2CSK4 or Pam3CSK4 were not caused by species spe-
cificity at CD14, SW620 cells were transiently transfected
with one of the following four receptor combinations:
human TLR2+TLR1+CD14, human TLR2+TLR1+equine
CD14, equine TLR2+TLR1+CD14, or equine TLR2+TL
R1+human CD14. The responses to Pam2CSK4 and
Pam3CSK4 at TLR2/1 were unaffected by the presence of
different species of CD14 (Figure 5B). Together, these data
confirm that residues in both equine TLR2 and equine
TLR1 are responsible for the low signal to Pam3CSK4
relative to Pam2CSK4.
Discussion
In this study, we have demonstrated functionality of the
equine TLR2/1 and TLR2/6 heterodimers, and shown
the receptors respond to LTA in virtually the same way
as those of human. We have also shown species differ-
ences are present in the responses of TLR2/1 to the syn-
thetic bacterial lipopeptides Pam2CSK4 and Pam3CSK4,
and that these differences are caused by both TLR2 and
TLR1 but not CD14.
Comparison of the equine TLR2, -1 and -6 sequences
with those of human and mouse show high sequence
homology, which is highest in the TIR domain. TIR do-
mains from different TLRs or TLR adaptor proteins are
highly conserved between different species, which repre-
sents their evolutionary nature as detectors of conserved
Figure 5 Effect of swapping species of TLR1 and CD14 on Pam2CSK4/Pam3CSK4 stimulation. SW620 cells were transiently transfected with
combinations of TLR2, TLR1 and CD14 (as indicated in the graphs) and reporter constructs NF-κB-luc and Renilla luciferase. Cells were stimulated
24 hours later with Pam2CSK4 at 20 ng/mL, Pam3CSK4 at 20 ng/mL, or medium alone. Cells were stimulated for six hours, lysed, and analysed for
luciferase activity. Data are from a representative experiment and expressed as triplicate mean ± SEM for that experiment. (A) Swapping the
species of TLR1 does not restore the equine response to Pam2CSK4/Pam3CSK4 to that of human. (B) Swapping the species of CD14 did not
affect responses to Pam2CSK4 or Pam3CSK4.
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the TLR2, -1 and -6 ligand binding regions are predom-
inantly conserved, with greatest amino acid variation at
the periphery of the TLR2 ligand binding pocket and
areas which would flank the ligand peptide groups. Evo-
lutionary preservation of the TLR2 binding pocket is
expected, since the majority of bacterial lipoproteins are
triacylated or diacylated, and would presumably require
insertion of two ester-bound acyl chains into the TLR2
pocket for receptor activation. Likewise, preservation of
the TLR1 binding pocket is necessary to allow insertion
of the third, amide-bound, acyl chain of triacylated
lipopeptides. TLR6 is thought to have arisen by evolution-
ary adaptation of TLR1 for recognition of diacylated
lipopeptides [27]. In the ligand-bound crystal structure of
murine TLR2/6, two phenylalanines, F343 and F365, block
the TLR6 binding pocket and prevent entry of a ligand
acyl chain [1]. This confers diacylated ligand recognition
only onto TLR6. These phenylalanines are conservedacross all mammalian species (Additional file 6). Equine
TLR6 is unable to recognise Pam3CSK4, which suggests
the function of F343 and F365, to prevent entry of an acyl
chain into the TLR6 binding pocket, is conserved in the
horse. The reduced conservation of residues that consti-
tute the ligand peptide-binding region in TLR2, -1 and -6
probably reflects the relative unimportance of this region
in ligand binding specificity. The shape and size of the lig-
and peptide head group affects ligand potency at TLR2 in
other species, due to effects on ligand positioning, how-
ever the interactions between receptors and ligand peptide
groups play only a minor role in ligand binding [1]. The
diversity of peptide groups between bacterial species may
have created host selection pressure by altering requisite
ligand sensitivity, leading to increased variation of this re-
ceptor region in response to species-specific pathogens.
All four pairs of equine/human TLR2/1 combinations
signalled similarly to Pam2CSK4 (Figure 5A). Species
specificity was seen with Pam3CSK4, with a partial, but
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either equine TLR2 or equine TLR1 was replaced with
its human counterpart. It is unlikely the lowered
Pam3CSK4 response is due to our L773W variant of
equine TLR1, since replacement of equine TLR1 with
human TLR1 should fully confer human TLR2/1 signal-
ling to Pam3CSK4, which it does not. Amino acid differ-
ences between human and equine TLR2 and TLR1 may
explain our species specificity data.
In the human TLR2/1/Pam3CSK4 crystal structure,
G313 of human TLR1 forms a hydrogen bond with K3 of
the ligand peptide head group, and replacement to S317 in
equine TLR1 could interfere with this interaction due to a
change in polarity [2]. There is also limited space for the
ligand head group between TLR2 and TLR1, and so the in-
creased size of the serine side chain could cause steric
interference with ligand binding. A reduction in signalling,
however, is not seen with Pam2CSK4, for which this inter-
action is also required. Absence of the ligand amide acyl
chain could, however, be permissive of a subtle shift in lig-
and orientation that negates the effect of S317. This shift
in orientation could also be favourable for Pam2CSK4
binding at equine TLR1, explaining the increased potency
of the ligand at equine TLR2/1 relative to human.
Structural comparison of the human and murine TLR2
crystals bound to Pam3CSK4 and Pam2CSK4 respect-
ively revealed small structural differences in the shape of
the ligand binding pocket, which may be attributed to
specific residues (human:murine L266F, P306L, T335L
and L355F) [1]. The structural differences between the
binding pockets are suggested to subtly affect acyl chain
interaction, irrespective of presence or absence of a third
ligand acyl chain. The former two residues are conserved
between horse and mouse, the latter two between equine
and human. The equine TLR2 binding pocket may
therefore be expected to form an intermediate shape be-
tween that of human and mouse. Subtle differences be-
tween the equine TLR2/1 lipopeptide responses could
then be attributed to the shape of the TLR2 binding
pocket, as well as ligand interactions with TLR1. There
is, however, significant permissible flexibility of the acyl
chains within the human and murine TLR2 pockets, and
so small alterations of the binding pocket shape should
not grossly affect ligand responses [28]. The R357Q vari-
ant residue present in our equine TLR2 construct is un-
likely to affect ligand behaviour selectively, since, for both
diacylated and triacylated ligands, the TLR2 pocket con-
tains the two ester-bound acyl chains of both ligands [1,2].
The considerable acyl chain flexibility within the pocket
should therefore allow for some variability in chain
conformation. Crystal structures of monomeric murine
TLR2 bound to Pam3CSK4 and Pam2CSK4 also show
identical conformations of the TLR2 pocket when the li-
gands are bound. LTA was equipotent at human andequine TLR2/1 and TLR2/6, therefore the shape and
flexibility of the TLR2 pocket does not obviously affect
binding to this ligand.
Our experiments with the equine TLRs were carried
out in human cells and, theoretically, there could be dif-
ferences in human MyD88 recruitment between human
and equine TLRs. A failure of MyD88 recruitment is un-
likely to explain our observed differential ligand effects
at equine TLR2/1, since diacylated ligand recognition
was highly similar for both species. It is, however, pos-
sible that a failure of Mal recruitment occurred, if equine
recognition of triacylated ligands requires Mal and hu-
man does not. Murine TLR2 responses to Pam3CSK4
are variably Mal-independent in primary cells, yet Mal-
dependent in immortalised cells, whereas responses to
MALP-2 (a diacylated ligand) are Mal-dependent in both
primary and immortalised cells [29-33]. The requirement
by human TLR2 for Mal in triacylated ligand signalling is
also unclear. Mal is required for signalling by human
TLR2 to MALP-2, and is degraded following Pam3CSK4
stimulation of an immortalised human macrophage cell
line in a manner similar to that following LPS stimulation
[34,35]. The specific requirement for Mal in human TLR2
signalling to triacylated lipopeptides has not been shown
definitively to the authors’ knowledge, however, and needs
defining in human and equine primary cells to facilitate
interpretation of our findings in the transfectant system.
Gram positive organisms frequently have diacylated
lipopeptides due to lack of apo-lipoprotein N-acetyltrans-
ferase (Lnt) enzyme, which adds a third acyl chain [36,37].
This enzyme is usually present in Gram negative organ-
isms, and so triacylated lipopeptides are more common in
Gram negative species. Given the horse is very sensitive to
LPS, it is tempting to speculate that a dampened TLR2
response to Gram negative organisms is evolutionarily ad-
vantageous, in order to prevent catastrophic immune re-
sponses to these pathogens [38]. The results of our study
support this hypothesis, but further testing with other
triacylated ligands, whole organisms and primary equine
cells are required to substantiate this theory.
In conclusion, TLR2/1 and TLR2/6 heterodimers are
likely to be important for bacterial detection in the horse,
but the species differences we see in bacterial lipopeptide
recognition may have important consequences for thera-
peutic drug design, such that human TLR2/1 antagonists
may not be as useful in the horse and vice versa. Likewise,
potential adjuvants designed to stimulate TLR2 may well
not translate well from humans to horses.
Additional files
Additional file 1: Expression of TLRs and responses to synthetic
ligands of SW620 and HEK293 cells. RT-PCR was performed on SW620
and HEK293 for TLR4 (lane 1), TLR2 (lane 2), TLR1 (lane 3), TLR6 (lane 4)
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SW620, and TLR1 was detected in HEK293. (B) After 35 cycles, TLR2 was
observed for both lines in the negative reaction (amplification of gDNA).
TLR1 was observed in positive and negative reactions for SW620. A bright
band was observed for TLR1 in HEK293 and not the negative control. A
band was observed for TLR6 in the HEK293 not observed in the negative
reaction, and observed at 30 cycles (not shown). A faint band appeared
for TLR6 in SW620 not observed in the negative control or at 30 cycles
(not shown). These findings indicate SW620 express TLR4, no TLR2, no
TLR1 and possible low expression of TLR6. HEK293 express no TLR4, no
TLR2, modest TLR1 and low TLR6. (C) SW620 were transiently transfected
with human TLR2, TLR2+1 or TLR2+6, or no exogenous TLR, with human
CD14 and reporters NF-κB-luc and Renilla luciferase, and stimulated 24
hours later with 20 ng/mL Pam2CSK4/Pam3CSK4 or medium alone. With
exogenous TLR2, SW620 respond weakly to Pam2CSK4 and not to
Pam3CSK4, consistent with low TLR6 expression. Exogenous TLR1 confers
strong Pam3CSK4 signalling, and exogenous TLR1/6 confers strong
Pam2CSK4 signalling. SW620 do not signal to these ligands without
exogenous TLR. (D) HEK293 were transfected as SW620 and stimulated
48 hours later as SW620. HEK293 respond to both ligands with
exogenous TLR2 only, consistent with endogenous TLR1/6 expression.
Pam3CSK4 signalling is improved with exogenous TLR1. HEK293 do not
signal to these ligands without exogenous TLR.
Additional file 2: Sequence identities of the equine receptor
constructs with human and murine receptors. Multiple sequence
alignments for total receptor sequence, ectodomain only, and TIR
domain only, reveal greatest conservation within the TIR domains.
Additional file 3: Sequence alignments of equine, human and
murine TLR2 (A), TLR1 (B) and TLR6 (C). Conserved residues across the
three species are highlighted in green. Conservation is highest in the TIR
domains for all three receptors, consistent with adaptor recruitment to
this region. Conserved residues are spread evenly across the ectodomains
and transmembrane domains.
Additional file 4: Variations between published equine receptor
sequences and our constructs. Models of the equine receptors were
generated in SWISS-MODEL, based on the published human or murine
crystal structures. (A) The equine TLR1 TIR structure (based on human
TLR1 TIR; [PDB:1FYV]) shows W773 (green) lies on the opposing side of
the TIR domain from the BB loop (yellow). (B) The equine TLR2 structure
(based on human TLR2) shows Q357 lies somewhat away from the main
dimerisation interface (yellow). Pam3CSK4 is shown in red. (C) The equine
TLR6 structure (based on murine TLR6) shows I452 lies well away from
the main dimerisation residues (yellow) and Pam2CSK4 binding site.
Pam2CSK4 is shown in red.
Additional file 5: Crystal structure of human TLR2 and TLR1 [PDB
code 2Z7X]. The TLR2 and TLR1 binding pockets are mostly lined with
equine/human conserved residues (grey), whereas the regions
surrounding the Pam3CSK4 (red) head group are mostly non-conserved
(TLR2: blue; TLR1: green).
Additional file 6: Sequence alignment of TLR6. The two
phenylalanines that block the TLR6 binding pocket (highlighted green)
are conserved across all domestic mammalian species.
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